Summary
The Food and Drug Administration (FDA) is enacting the Research to Accelerate Cures & Equity (RACE) for Children Act amends and updates the Pediatric Research Equity Act (PREA). RACE Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This paper discusses the need for and the importance of pediatric research, the RACE Act, and how it applies to precision medicine.
Register to download
RACE Act Prompts More Pediatric Clinical Trials for Oncology Drug Developers
You may also be interested in:
Case Study
Early Phase Innovative Pediatric Oncology Program Achieves Successful First Multiple Solid Tumors Study
PRA partnered with the sponsor’s new pediatric oncology department on an innovative pediatric oncology program. The program provided early evaluation…
Blog
The RACE for Children Act
In the US, legislation such as the Better Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) have helped to…
White Paper
Parents as Gatekeepers for Children with Cancer
The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular…